TITAN BIOTECH LTD. (TITANBIO)

BSE: ₹442.25
Stock Performance
Corporate Announcements
Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper publication of the Audited Financial Results (Standalone & Consolidated) for fourth quarter and year ended March 31, 2026

2026-06-01 10:53:07
Re-Appointment Of Cost Auditor For Financial Year 2026-2027

Intimation for re-appointment of Cost Auditor of the Company

2026-05-30 16:04:46
Corporate Action-Board to consider Dividend

The Board of Director of the Company has recommended a dividend of Rs. 0.50 paisa per Equity Share

2026-05-30 15:59:32
2026-05-30 15:55:33
Board Meeting Outcome for Outcome Of The Board Meeting Of Titan Biotech Limited Held Today I.E. 30Th May, 2026

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors, at its meeting held today i.e. Saturday 30th May, 2026, Approval of Audited Financial Results For The Fourth Quarter And Year Ended 31st March, 2026, Recommendation of Dividend, re appointment of Cost Auditor, and Appointment of Scrutinizer

2026-05-30 15:48:40
Intimation Regarding Second 100 Days Campaign – “Saksham Niveshak”

Second 100 days Campaign under Saksham Niveshak Yojna

2026-05-06 18:00:15
Announcement under Regulation 30 (LODR)-Press Release / Media Release

Newspaper publication regarding special window for re-lodgement of transfer request and dematerialisation of physical shares.

2026-05-06 11:31:48
Compliances-Reg.24(A)-Annual Secretarial Compliance

Annual Secretarial Compliance Report for the financial year ending March 31, 2026

2026-05-04 12:25:01
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyTitan Biotech Ltd 2CIN NO.L74999RJ1992PLC013387 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: CHARANJIT SINGH Designation: COMPANY SECRETARY EmailId: hrd@titanbiotechltd.com Name of the Chief Financial Officer: PREM SHANKAR GUPTA Designation: CHIEF FINANCIAL OFFICER EmailId: premgupta@titanbiotechltd.com Date: 28/04/2026 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.

2026-04-28 15:59:52

Quarterly Financials

Consolidated Standalone
Particulars Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
Revenue from Operations 34.75 43.43 45.98 39.92 43.11 39.89 38.28 35.17 46.50 54.35 56.51 48.83
YOY Revenue Growth % -0.71% 3.81% 51.58% 8.37% 24.08% -8.14% -16.75% -11.9% 7.84% 36.26% 47.63% 38.85%
Other Income 0.28 0.55 0.44 0.48 0.62 0.32 1.59 1.38 0.72 1.32 1.26 2.11
Total Income 35.03 43.98 46.42 40.40 43.74 40.21 39.87 36.55 47.22 55.68 57.76 50.94
Total Expenses + 27.94 35.85 36.48 34.02 36.22 33.49 34.76 31.52 39.11 46.46 47.20 40.66
Cost of Materials Consumed 18.92 20.45 20.28 21.25 22.35 16.19 19.64 17.30 18.55 27.43 27.28 25.91
Employee Benefit Expense 5.42 5.47 6.02 6.80 6.27 6.50 6.67 6.94 7.01 7.38 8.53 9.44
Other Expenses 6.88 8.03 7.82 7.75 6.83 8.12 8.43 8.64 6.80 11.60 9.78 10.86
Operating Profit 6.81 7.57 9.50 5.90 6.89 6.40 3.52 3.65 7.39 7.89 9.31 8.18
OPM % 19.6% 17.4% 20.7% 14.8% 16% 16% 9.2% 10.4% 15.9% 14.5% 16.5% 16.7%
Profit Before Tax + 7.09 8.13 9.94 6.37 7.52 6.72 5.10 5.03 8.11 9.22 10.56 10.28
Tax Expense 0.93 1.60 2.77 1.38 1.12 0.02 0.71 0.98 1.25 1.45 2.03 3.55
Tax % 13.1% 19.7% 27.8% 21.6% 14.9% 0.3% 14% 19.5% 15.4% 15.8% 19.3% 34.6%
Profit After Tax 6.16 6.52 7.17 5.00 6.40 6.70 4.39 4.05 6.86 7.76 8.53 6.73
EPS (Basic) 7.47 7.89 8.68 5.86 7.74 8.10 5.31 4.90 8.30 9.40 10.32 1.63

Yearly Financial Results

Consolidated Standalone
Particulars Mar 2026 Mar 2025 Mar 2024 Mar 2023 Mar 2022 Mar 2021
Revenue from Operations 206.19 156.45 164.07 144.00 152.81 142.24
YOY Revenue Growth % 31.79% -4.65% 13.94% -5.77% 7.43% -
Other Income 5.41 3.91 1.75 1.94 1.02 0.79
Total Income 211.60 160.36 165.82 145.94 153.83 143.03
Total Expenses + 173.43 136.00 134.29 117.83 115.63 100.00
Cost of Materials Consumed 99.16 75.48 80.89 70.81 75.48 67.30
Employee Benefit Expense 32.36 26.38 23.71 18.21 16.14 14.05
Other Expenses 39.03 32.02 30.47 26.40 20.80 17.49
Operating Profit 32.76 20.45 29.78 26.17 37.18 42.24
OPM % 15.9% 13.1% 18.2% 18.2% 24.3% 29.7%
Profit Before Exceptional 38.17 24.37 31.53 28.12 38.20 43.03
Exceptional Items 0.00 0.00 0.00 0.00 0.00 -0.32
Profit Before Tax + 38.17 24.37 31.53 28.12 38.20 42.71
Tax Expense 8.29 2.84 6.68 3.27 9.45 11.00
Tax % 21.7% 11.6% 21.2% 11.6% 24.8% 25.8%
Profit After Tax 29.89 21.53 24.85 24.84 28.74 31.71
EPS (Basic) 7.23 26.06 28.64 30.06 30.66 36.71

Balance Sheet

Particulars Mar 2026 Mar 2025 Mar 2024 Mar 2023 Mar 2022 Mar 2021
ASSETS
Non-Current Assets + 128.64 95.67 84.41 66.21 52.05 41.39
Property, Plant & Equipment 51.34 57.16 51.94 35.81 42.05 33.52
Capital Work in Progress 1.73 1.68 2.53 13.29 7.97 0.27
Non-Current Investments 60.36 32.77 28.19 15.41 0.00 0.00
Goodwill 0.00 0.00 0.00 0.00 0.00 0.00
Other Intangible Assets 0.08 0.11 0.07 0.09 0.10 0.09
Current Assets + 85.24 79.04 72.17 68.31 91.35 59.33
Inventories 55.77 50.72 45.57 36.17 42.29 32.54
Trade Receivables 22.83 18.82 18.66 21.01 21.67 18.10
Cash and Cash Equivalents 1.48 5.13 2.84 4.86 15.61 5.45
Current Investments 0.00 0.00 0.00 0.00 0.00 0.00
LIABILITIES & EQUITY
Total Equity 181.55 153.40 133.45 109.91 105.41 72.48
Equity Share Capital 8.26 8.26 8.26 8.26 8.26 8.26
Other Equity 173.28 145.14 125.19 101.65 90.40 60.49
Non-Current Liabilities 6.37 3.57 4.00 4.25 12.76 9.13
Current Liabilities 25.96 17.74 19.13 20.35 25.23 19.11
Total Liabilities 32.34 21.30 23.13 24.60 37.99 28.24

Cash Flow Statement

Particulars Mar 2026 Mar 2025 Mar 2024 Mar 2023 Mar 2022 Mar 2021
Cash from Operating Activities 30.42 20.12 21.15 21.18 22.86 19.24
Cash from Investing Activities -34.41 -9.87 -20.30 -20.73 -18.79 -8.08
Cash from Financing Activities 0.34 -7.96 -2.87 -2.40 6.08 -7.54
Net Increase/Decrease in Cash -3.65 2.29 -2.02 -1.95 10.16 3.62